Novel HIV Immunization Regimens and Immune Implications
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: 30 November 2024 | Viewed by 178
Special Issue Editors
Interests: HIV vaccine development and evaluation; animal models for HIV, HCV, Lassa, and COVID-19 vaccine development; B cell and T cell analysis, and antibody development and characterization
Special Issue Information
Dear Colleagues,
The elicitation of a protective immune response is the goal of vaccine research for HIV-1 and other pathogens. Novel vaccine platforms, such as nanoparticles, virus-like particles (VLPs), and mRNA LNP platforms, combined with new adjuvants and immunization regimens, have provided promising approaches to vaccine development for emerging disease pathogens and for difficult-to-achieve vaccines. Understanding the implication of vaccine-elicited immune response with these new immunogens/regimens will move the field forward and help the evaluation and development of more effective vaccine products.
Manuscripts reporting on new HIV-1 immunogens, novel immunization regimens, immune response analysis with new antigens and methods, immune response monitoring, and new animal models are welcome for this Special Issue.
This Special Issue encourages the submission of original articles, systematic reviews, meta-analyses, short communications, and other types of articles that describe the application of new immunogens and immunization regimens, or the association of immune responses to vaccine outcomes.
Dr. Hongying Duan
Dr. Rui Kong
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- HIV-1
- immunogen
- vaccine efficacy
- immune response
- B cells
- T cells
- antibody
- adjuvant
- immunization regimen
- animal model
